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Abstract
Purpose: To quantify the radiobiological advantages obtained by an Improved Forward Planning technique (IFP)
and two IMRT techniques using different fractionation schemes for the irradiation of head and neck tumours. The
conventional radiation therapy technique (CONVT) was used here as a benchmark.
Methods: Seven patients with head and neck tumours were selected for this retrospective planning study. The
PTV1 included the primary tumour, PTV2 the high risk lymph nodes and PTV3 the low risk lymph nodes. Except for
the conventional technique where a maximum dose of 64.8 Gy was prescribed to the PTV1, 70.2 Gy, 59.4 Gy and
50.4 Gy were prescribed respectively to PTV1, PTV2 and PTV3. Except for IMRT2, all techniques were delivered by
three sequential phases. The IFP technique used five to seven directions with a total of 15 to 21 beams. The IMRT
techniques used five to nine directions and around 80 segments. The first, IMRT1, was prescribed with the
conventional fractionation scheme of 1.8 Gy per fraction delivered in 39 fractions by three treatment phases. The
second, IMRT2, simultaneously irradiated the PTV2 and PTV3 with 59.4 Gy and 50.4 Gy in 28 fractions, respectively,
while the PTV1 was boosted with six subsequent fractions of 1.8 Gy. Tissue response was calculated using the
relative seriality model and the Poisson Linear-Quadratic-Time model to simulate repopulation in the primary
tumour.
Results: The average probability of total tumour control increased from 38% with CONVT to 80% with IFP, to 85%
with IMRT1 and 89% with IMRT2. The shorter treatment time and larger dose per fraction obtained with IMRT2
resulted in an 11% increase in the probability of control in the PTV1 with respect to IFP and 7% relatively to IMRT1
(p < 0.05). The average probability of total patient complications was reduced from 80% with CONVT to 61% with
IFP and 31% with IMRT. The corresponding probability of complications in the ipsilateral parotid was 63%, 42% and
20%; in the contralateral parotid it was 50%, 20% and 9%; in the oral cavity it was 2%, 15% and 4% and in the
mandible it was 1%, 5% and 3%, respectively.
Conclusions: A significant improvement in treatment outcome was obtained with IMRT compared to conventional
radiation therapy. The practical and biological advantages of IMRT2, employing a shorter treatment time, may
outweigh the small differences obtained in the organs at risk between the two IMRT techniques. This technique is
therefore presently being used in the clinic for selected patients with head and neck tumours. A significant
improvement in the quality of the dose distribution was obtained with IFP compared to CONVT. Thus, this beam
arrangement is used in the clinical routine as an alternative to IMRT.
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Important evolutions in the treatment efficacy of head
and neck tumours have occurred with the introduction
of chemoradiation [1] and the development of Intensity
Modulated Radiation Therapy (IMRT) [2]. Chemother-
apy has improved overall survival, but at a cost of an
increase in patient side-effects [1]. The concave target
volume adjacent to radiosensitive organs at risk creates
several difficulties for uniform beam radiation therapy
but makes it very interesting for IMRT. The conven-
tional uniform beam technique is mostly based on an
arrangement of lateral opposed photon and electron
beams. No attempt to spare the parotids glands is then
made and xerostomia becomes the most important
complication in patients undergoing radiation therapy
with this beam configuration [3-5].
More complex and refined techniques, based on a lar-
ger number of beams, arcs, and class solutions have
been proposed [6-10]. Developments in the treatment
units have enabled the fast and automatic delivery of
these complex techniques and an update from older
techniques in the irradiation of head and neck tumours
is thus mandatory. Ideally all patients would be treated
with IMRT, but the implementation of this technique in
the clinical routine is a long and cumbersome task
which strongly depends on the human and economical
resources of the institution. A slow progression is
a d v i s e dt og i v et ot h et e a mt h eo p p o r t u n i t yt ol e a r n
about the new technology and adapt to the new proto-
cols. Thus, the transition pe r i o df r o mc o n f o r m a lr a d i a -
tion therapy to IMRT may become long. Even then not
all patients may be candidates for IMRT. Patient general
health status, among many other factors, may signifi-
cantly influence the selection of the irradiation techni-
que. Therefore, alternatively to IMRT, an Improved
Forward Planning (IFP) technique was tested. This is a
simplified intensity modulated beam technique based on
direct and manual optimization which uses no more
than three segments per direction and five to seven
coplanar gantry angles.
Several treatment planning studies have evaluated the
benefits of IMRT for the irradiation of head and neck
tumours [7,11-14] and an increasing number of clinical
reports are becoming available [3-5,15-18]. But due to
the fast and recent development of IMRT technology
there is not yet a standard irradiation strategy [19].
Often the treatment irradiation technique is decided by
each institution based on its own experience with uni-
form beams since the best way to deliver IMRT remains
unclear. Thus, in this study the advantages of two IMRT
treatment techniques using different fractionations were
investigated. The first reproduces the conventional frac-
tionation schedule used in our department which is
based on three sequential treatment phases that deliver
three different dose levels. However, for IMRT the
simultaneous delivery of two different dose levels, aim-
ing to minimize the number of treatment phases, has
dosimetric and practical advantages. Simultaneous inte-
grated boost techniques have therefore been extensively
proposed in the literature [11,12,14-16,20,21]. Similarly,
the second studied IMRT technique was assigned with
two different prescription dose levels delivered simulta-
neously to different PTVs and then the primary lesion
was boosted by a second treatment plan. By reducing
the overall treatment time biological benefits are also
expected due to the fast proliferation rate characterizing
head and neck tumours [22].
With the clinical implementation of an Improved For-
ward Planning technique and more recently the imple-
mentation of IMRT at our institution, this study aims at
evaluating the radiobiological advantages of these new
treatment techniques. Some treatment planning studies
have determined the probability of complications
[13,23]. Kam et al 2003 [24] calculated the probability of
tumour control but without considering the effect of
tumour repopulation. Still most treatment planning stu-
dies have been mostly focused on dosimetric considera-
tions [7,11-14]. However when comparing treatment
techniques using different fractionations a dosimetric
evaluation is not sufficient since the impact of the dose
per fraction and overall treatment time are not consid-
ered. For fast repopulating tumours irradiated with an
integrated boost such variables become fundamental cri-
teria in plan evaluation and selection. A complete radio-
biological study where an estimation of the benefits
versus the risks obtained with the biological dose escala-
tion prescribed with integrated boost techniques in head
and neck tumours has not yet been made. By quantify-
ing the probability of tissue response to the proposed
fractionation schedules the IMRT technique that repre-
sents the best compromise between the therapeutic ben-
efits and practical feasibility was selected.
Materials and methods
Patients and prescription
Seven patients representing typical cases of head and
neck tumours at our institution stage I-III were used in
this retrospective planning study: nasopharynx (2), hypo-
pharynx (2), oropharynx (2) and base of the tongue (1).
Each patient was immobilized with a thermoplastic
mask and a CT scan with a 3 mm slice thickness was
acquired for treatment planning.
T h eP T V 1i n c l u d e dt h ep r i m a r yt u m o u r ,t h eP T V 2
the high risk lymph nodes (cervical and supraclavicular)
and PTV3 the low risk lymph nodes (also cervical and
supraclavicular) (Figure 1). The main organs at risk
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Page 2 of 13delineated, and used in the optimization, were the spinal
cord, parotids, mandible, oral cavity, lungs and remain-
ing surrounding normal tissue. To account for small
positioning errors and thus to guarantee maximum
spinal cord protection the spinal canal was delineated
and used in the optimization as a non-uniform margin
surrounding the spinal cord. For plan evaluation the
n o r m a lt i s s u ei n s i d et h eP T V ,t h el a r y n x ,t h et h y r o i d ,
oesophagus, brainstem and brain were also considered.
Except for the conventional technique where a total
maximum dose of 64.8 Gy was prescribed to the PTV1,
70.2 Gy, 59.4 Gy and 50.4 Gy were prescribed respec-
tively to PTV1, PTV2 and PTV3. However, the different
fractionation schemes described in Table 1 were used by
the different irradiation techniques.
For IMRT two different types of planning objectives
were established depending on the priority of the region of
interest. For the PTV and spinal cord constraints were
defined that have to be reached for plan approval. At least
95% of the volume of the PTVs should receive 95% of the
prescribed dose. The overdosage in the PTVs should not
surpass 107%. Also, a maximum dose constraint in the
spinal cord of 45 Gy was imposed. For the organs at risk
with lower priority general objectives, based on well
accepted clinical tolerance dose values, were defined: the
mean dose in the parotids should be as low as possible
aiming at achieving at least less than 26 Gy [25]. A maxi-
mum dose objective of 50 Gy to the mandible and oral
cavity and 70 Gy to the surrounding normal tissue were
also considered. These were used as initial guidelines in
the start of the optimization but were successively adjusted
for each patient until normal tissue sparing was maxi-
mized without compromising target coverage.
Treatment techniques
The conventional technique (CONVT), used here as a
benchmark, was based on a configuration using photon
and electron beams. The total treatment was composed
by three sequential phases delivering three different
dose levels. In the first phase the aim was to irradiate
the total PTV with 45 Gy (Table 1). The head PTV was
irradiated with parallel opposed conformal photon
beams, with or without wedges. The neck PTV, covering
the supraclavicular lymph nodes, was irradiated with
anterior-posterior and/or oblique photon beams. In the
second treatment phase, to spare the spinal cord, two
lateral electron beams irradiated the posterior part of
the PTV while two lateral parallel opposed photon
beams irradiated the anterior region of the head PTV to
54 Gy. The last treatment phase boosted the primary
tumour, PTV1, with additional 10.8 Gy with oblique
Figure 1 Beams eye view of the posterior portal used in the IFP technique. This portal is composed by three segments: the first was
conformal to the total PTV, whereas the second and third segments irradiated the PTV lying on the right and left side of the spinal cord,
respectively. In this patient, the PTV1 includes the primary tumour and an adenopathy shown in brown. The high risk lymph nodes, PTV2, are
shown in red and the low risk lymph nodes are shown in orange.
Table 1 Nominal prescribed dose for the different
treatment techniques studied
1
st phase 2
nd phase 3
rd phase
CONVT PTV3 45.0Gy
1.8Gy/fx
PTV2 9Gy 1.8Gy/
fx
PTV1 10.8Gy
1.8Gy/fx
Total Prescr.
D
45Gy 54Gy 64.8Gy
IFP PTV3 50.4Gy
1.8Gy/fx
PTV2 9Gy 1.8Gy/
fx
PTV1 10.8Gy
1.8Gy/fx
IMRT1 PTV3 50.4Gy
1.8Gy/fx
PTV2 9Gy 1.8Gy/
fx
PTV1 10.8Gy
1.8Gy/fx
Total Prescr.
D
50.4Gy 59.4Gy 70.2Gy
IMRT2 PTV3 50.4Gy
1.8Gy/fx
PTV2 59.4Gy
2.12Gy/fx
PTV1 10.8Gy
1.8Gy/fx
Total Prescr.
D
59.4Gy 70.2Gy
PTV1 includes the primary tumour;
PTV2 includes the high risk lymph nodes;
PTV3 includes the lymph nodes with possible infiltration of microscopic
disease.
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(Table 1).
IFP is a simplified IMRT technique based on direct
planning optimization. The first course used five to
seven gantry directions with a total of 15 to 21 beams
with a single isocenter. Each incidence was composed
by three segments: the first was conformal to the total
PTV, whereas the second and third segments irradiated
the PTV lying on the right and left side of the spinal
cord, respectively (see Figure 1 for the posterior inci-
dence). This beam configuration irradiated the total
PTV to a maximum of 50.4 Gy. The second and third
treatment phases boosted the PTV2 and PTV1, respec-
tively, with oblique conformal photon beams to 59.4 Gy
and 70.2 Gy respectively using the fractionation scheme
shown in Table 1. Beam weight, directions and energy
were manually optimized in a trial and error process
until homogeneity criteria were met and the dose in the
organs at risk was reduced as much as possible.
With IMRT, depending on the tumour case and
patient geometry, five to nine directions may be suffi-
cient to obtain the almost optimal dose distribution
without the need for direction optimization [26]. Thus
in this study beam configurations using five, seven or
nine equidistant photon beams of 6MV were tested for
all patients. The best plan was selected for this compari-
son. To keep treatment quality and irradiation time
within reasonable limits no more than 80 segments
were used. IMRT1 used the conventional fractionation
scheme of 1.8 Gy per fraction during 39 fractions in
three phases (Table 1). The optimization of the plan of
the second treatment phase assumed the pre-planned
dose distribution of the first treatment plan. However,
due to software limitations of the Konrad treatment
planning system the third treatment course was opti-
mized independently. The second IMRT technique,
IMRT2, simultaneously irradiated the PTV2 and PTV3
with 59.4 Gy and 50.4 Gy, respectively, during 28 frac-
tions, while the PTV1 was boosted with additional six
fractions of 1.8 Gy (Table 1). Again, the optimization of
the boost plan was based on the dose distribution of the
first treatment plan.
Forward optimized planning treatment techniques, like
the conventional and the IFP, were planned in the treat-
ment planning system Oncentra Masterplan v3.1 (OMP)
from Nucletron using a dose grid of 3 × 3 × 3 mm
3.
The dose was calculated using a pencil beam algorithm
with corrections for heterogeneities for photon beams
and Monte Carlo for electron beams.
IMRT plans were optimized in the treatment planning
system Konrad v2.2.23 from Siemens using a dose grid
o f4×4×4m m
3 and a pencil beam algorithm. The
plans were then imported into the treatment planning
system OMP and the dose distribution was recomputed
using the same dose algorithm and dose grid as for the
direct optimized planning techniques.
Plan evaluation
Dose prescription for head and neck tumours was
defined in three dose levels. This is generally delivered
by three treatment phases and the total nominal dose is
thus given by the arithmetical sum of the dose delivered
by each plan. But to determine the probability of tissue
response for treatments using fractionation schemes
that deviate from the conventional fraction of 2 Gy,
from which dose response parameters where derived
from, a correction for fractionation is needed. This cor-
rection will convert the real dose distribution into a
dose distribution based on a 2 Gy fractionation, here
referred as D2Gy. To make this fractionation conversion
the concept of Biologically Effective Dose [27], BED, was
used to sum and convert the 3 D dose distribution of
each treatment phase into one 3 D dose matrix based
on 2 Gy fractions through the equality:
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where Np is the number of plans, Di is the total nom-
inal or physical dose in each voxel delivered in phase i
in fractions of size di. a/b is the ratio of the Linear-
Quadratic model which was assumed to be 10 for
tumour tissues and 3 for normal tissues. Tpot is the
tumour potential doubling time, T is the overall treat-
ment time for the prescribed fractionation and Tk is the
time at which repopulation begins. D2Gy is the total
dose delivered during T2Gy days that results in the same
biological effect. This overall treatment time was related
to the number of fractions, n2Gy, through the expression,
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where flr rounds the number to the smallest integer
and rem is the remainder after the division. T2Gy was
thus determined through the minimization of equation
(1).
Head and neck tumours are fast proliferating tumours
and therefore repopulation was simulated in this study
using the Poisson Linear-Quadratic-Time model [27].
Altered fractionation schemes compared to 2 Gy frac-
tions have demonstrated clinical benefits in terms of
local-regional control [28,29]. However, the advantages
obtained by reducing treatment time were mainly seen
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the response of the nodal areas was obtained. This may
suggest that repopulation occurs mainly in the primary
tumour and therefore repopulation effects were mod-
elled only in the primary tumour, PTV1, using a Tpot of
3d a y sa n daTk of 28 days [22]. In the lymph nodes
regions: PTV2 and PTV3, proliferation during the ther-
apy was disregarded. Thus for these structures and for
all the normal tissues the expressions used to determine
tissue response are the same as described here but the
terms related to tumour repopulation were ignored.
The probability of tissue response, P,o far e g i o no f
interest that is irradiated uniformly with a dose D2Gy
was determined using the expression,
Pe D D
T
=− − −
+
exp{ exp[
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  2Gy2 Gy
                          
p
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o ot
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a and b are the fractionation parameters of the
Linear-Quadratic model and were determined using the
expressions,
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D50 i st h ed o s ew h i c hg i v e sa5 0 %r e s p o n s ea n dg is
the maximum normalized dose-response gradient and
are specific to each tissue and endpoint. The dose-
response parameters for the organs at risk used in the
optimization are defined in Table 2[30-34]. For other
organs, considered only for plan evaluation, the dose
response values from Ågren 1995 [32] and Mavroidis et
al 2006 [34] were used. d is the reference dose per frac-
tion of 2 Gy. The seriality model by Källman et al 1992
[35] was used to determine the probability of tissue
response to a heterogeneous dose distribution. Thus the
probability of injury of the organ j, PI
j , was given by
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where Δvk is the fractional sub-volume of the organ
that is irradiated with dose Dk and M is the total num-
ber of bins. P
j(Dk) is determined using the Linear-Quad-
ratic-Time-Poisson model as described by equation (3).
s is the relative seriality parameter that characterizes the
internal organization of that organ. A relative seriality
close to zero corresponds to a more parallel structure,
whereas s ≈ 1 corresponds to a more serial structure.
The total probability of complications was then given
by,
PP I I
j
j
N
=− − ()
= ∏ 11
1
(6)
where N is the total number of organs at risk. Tumour
control is obtained when the N targets are controlled
and therefore the total probability of tumour control PB,
was given by,
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where P
j
B is the probability of eradicating tumour j.
The probability of uncomplicated tumour control, P+,
[35] used to quantify treatment outcome, was estimated
using the approximation:
PPP BI + =− (8)
Plan evaluation was based on tissue responses but also
on conventional physical measures. To eliminate clini-
cally insignificant high or low values of maximum and
minimum doses, the dose delivered to 0.1 cm
3 was used
as a surrogate for maximum and minimum dose,
respectively.
The Wilcoxon matched pairs test was used to test the
significance of the differences obtained between the
techniques studied.
Results
The IFP technique significantly enhanced the quality of
the dose distribution compared to the conventional
treatment (Figure 2). A dose escalation to 70.2 Gy was
Table 2 Dose-response parameters used in the relative
seriality model for the organs at risk included in the
optimization [30-33]
Tissue D50/
Gy
g s Endpoint
PTV1 51.0 7.5 - Control
PTV2 44.0 4.0 - Control microscopic disease
PTV3 38.0 2.0 - Control microscopic disease
Spinal cord 57.0 6.7 1.00 Myelitis necrosis
Parotids 46.0 1.8 0.01 Xerostomia
Mandible 70.3 3.8 1.00 Marked limitation of joint function
Oral cavity 70.0 3.0 0.50 Mucositis
Lungs 30.0 1.0 0.01 Severe radiation pneumonitis-
fibrosis
Surrounding
tissue
65.0 2.8 1.00 Necrosis
D50 is the dose which gives a 50% response,
g is the maximum normalized dose-response gradient,
s is the relative seriality parameter.
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tumour control, PB, increased from 38.1% with the con-
ventional technique (CONVT) to 79.7% with IFP; p <
0.05 (Figure 2 and Table 3). Simultaneously, the average
probability of total patient complications, PI,w a s
reduced 19.1% (p < 0.05).
In Figure 3 the response and the dosimetric data
obtained for the main organs at risk for head and neck
radiation therapy are shown. The biologically converted
dose values to a fractionation scheme of 2 Gy per frac-
tion are shown by the colour bars. For comparison the
nominal or physical dose values are also illustrated by
the grey bars. The probability of severe complications in
the ipsilateral parotid was reduced from 62.8% with
CONVT to 42.2% with IFP and in the contralateral par-
otid from 49.9% to 19.7%, respectively; p < 0.05 (Figure
3). This was mainly due to a significant reduction in the
mean dose in the ipsilateral parotid from 50.5 ± 6.8 Gy
with the CONVT technique to 43.0 ± 10.9 Gy with the
IFP technique and from 46.0 ± 7.3 Gy to 35.7 ± 9.0 Gy
in the contralateral parotid, respectively; p < 0.05 (Figure
3). However, the prescribed dose escalation increased
the dose in the oral cavity, the mandible and the normal
tissue stroma inside the PTV and therefore the
probability of complications in each of these structures;
p < 0.05 (Figure 3). Although, the spinal cord was now
better protected with this complex forward treatment
technique; p < 0.05, this had no impact on the probabil-
ity of complications since in all cases the probability of
injury for this organ was almost zero.
With IMRT1 treatment outcome, as quantified by the
probability of uncomplicated tumour control P+,h a s
increased in average to 57.2% compared to 18.8%
obtained with IFP; p < 0.05 (Figure 2). This was mainly
due to the better dose protection of the organs at risk
and therefore the total probability of complications was
reduced from 60.9% with IFP to 28.1% with IMRT1; p <
0.05 (Figure 2). The probability of complications in the
ipsilateral parotid was reduced 27% relatively to the IFP
technique and more than 9% in the contralateral paro-
tid; p < 0.05 (Figure 3). This corresponded to a decrease
i nt h em e a nd o s eo fa l m o s t1 1G ya n d5G y( p<0 . 0 5 ) ,
respectively. At the same time the probability of compli-
cations in the oral cavity and mandible was reduced
12% (p < 0.05) and 3% (n.s.), respectively (Figure 3).
IMRT1 increased the average probability of total
tumour control almost 6% compared to the IFP techni-
que due to the better target coverage; p < 0.05 (Figure
2). However due to the shorter fractionation schedule of
IMRT2, with less seven treatment days, the average
probability of total tumour control increased from
79.7% with IFP to 89.4% with IMRT2 (p < 0.05). This
was mostly due to the 11% better probability of local
tumour control, i.e. in the PTV1, obtained with IMRT2
compared to IFP; p < 0.05 (Figure 4). Biologically con-
verted dose to a fractionation of 2Gy fractions, D2Gy,
indicated that, for about the same nominal dose (grey
bars in Figure 4), the mean dose delivered in the PTV1
was now almost 10 Gy larger than the mean dose deliv-
ered by IFP or IMRT1; p < 0.05 (colour bars in Figure 4
and Table 3).
Despite the better probability of tumour control with
IMRT2, the estimated treatment outcome P+ was about
the same for the two IMRT techniques (Figure 2).
IMRT2 further improved the sparing of the contralateral
parotid compared to IMRT1 but, for the same physical
dose, increased the average probability of complications
in the ipsilateral parotid 4.4% (Figure 3). For individual
patients IMRT2 performs in fact as good as or even
slightly better than IMRT1 in four out of seven patients
(Figure 5). However none of these small differences
were statistically significant.
All patients benefited from more complex radiation
therapy techniques (Figure 5). The average probability
of complications in the ipsilateral parotid was reduced
with IFP but a further significant reduction was obtained
with IMRT. In the contralateral parotid the average
probability of injury was significantly reduced already
P+ PB PI
0
25
50
75
AVERAGE PROBABILITY OF PATIENT RESPONSE P/%
CONVT
IFP
IMRT1
IMRT2
Figure 2 Average response values for P+, PB and PI.A v e r a g e
values and standard deviation for the probability of uncomplicated
tumour control, P+, the total probability of tumour control, PB, and
the total probability of severe complications, PI. Sophisticated
radiation treatment techniques have significantly increased the
probability of total tumour control first due to the prescribed dose
escalation and second due to the biological dose escalation
obtained with IMRT2. The probability of complications was already
significantly reduced with IFP compared with CONVT, but with IMRT
a further significant decrease was obtained. The differences
obtained for the treatment outcome and the probability of
complications between IMRT1 and IMRT2 were not statistically
significant.
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Page 6 of 13with IFP but only slightly further reduced with IMRT
(horizontal lines in Figure 5). As expected, patients with
tumours in the nasopharynx have the largest probability
of complications in the parotids for all treatment techni-
ques. For some of the remaining patients the probability
of complications in the parotids was still large with IFP,
but significantly reduced with IMRT.
Discussion
The radiobiological evaluation of competing plans is
a d v a n t a g e o u ss i n c eb yu s i n gt h ef u l l3Dd o s ed i s t r i b u -
tion the impact of factors like dose per fraction and
total treatment time are accounted for in the determina-
tion of the probability of response. Additionally due to
the heterogeneity and limitations of the planned dose
distribution significant differences, up to 10%, between
the estimated outcomes calculated using the prescrip-
tion and the final plan were obtained (Table 3). These
differences may be even more pronounced if the deliv-
ered dose distribution could be considered [36]. Treat-
ment patient setup deviations and anatomical
distortions may deteriorate the quality of the planned
dose distribution. These are important aspects that
should be considered during plan optimization and
delivery to guarantee treatment success. A radiobiologi-
cal evaluation is thus a very useful tool to complement
physical measures helping to score the quality of the
plans.
In this retrospective planning study all dose distribu-
tions were converted into a common fractionation sche-
d u l eo f2G yt h u ss i m p l i f y i n gt h ed o s i m e t r i ca n a l y s i s .
Although the four techniques were planned using differ-
ent prescription dose, fraction sizes and total treatment
time, a dosimetric comparison can be made by analysing
the biological dose (colour bars in Figure 3, 4). Thus, for
example with IMRT2 the biological dose escalation in
the primary tumour became immediately evident (Table
3).
IMRT, forward or inversely optimized, were radiobio-
logically and dosimetrically significantly superior to con-
ventional plans (Figure 2, 3, 4). Three more fractions of
1.8 Gy, in addition to the conventional prescription,
were thus prescribed to escalate the dose in all the
PTVs. This resulted in an increase in the probability of
tumour cure and an immediate advantage for IMRT.
Prescribed dose is generally limited by the tolerance of
the organs at risk and the capabilities of the irradiation
technique to protect such normal tissues. Thus depend-
ing on the strategy employed the benefits of a new treat-
ment may be obtained from a gain in the probability of
tumour cure, a reduction in the probability of patient
injury or both. To maximize the potential of a new
Table 3 Relation between prescribed and planned dose when the 3D dose distribution is considered for plan
evaluation and corresponding probability of tumour control
D/Gy
prescr.
BED/Gy
prescr.
D2Gy/Gy
prescr.
D2Gy ± SD/Gy
planned
PB /%
prescr.
PB ± SD/%
planned
CONVT PTV1 64.8 62.2 58.0 57.2 ± 3.1 66.7 48.8 ± 21.6
PTV2 54.0 63.7 53.1 56.5 ± 2.3 93.4 86.5 ± 7.3
PTV3 45.0 53.1 44.3 52.7 ± 1.5 76.7 89.2 ± 3.4
Total 47.8 38.1 ± 17.6
IFP PTV1 70.2 66.5 64.0 64.1 ± 1.0 89.4 87.6 ± 2.9
PTV2 59.4 70.1 58.4 63.3 ± 1.6 98.3 98.7 ± 0.7
PTV3 50.4 59.5 49.6 53.6 ± 1.1 88.9 92.2 ± 0.8
Total 78.1 79.7 ± 2.5
IMRT1 PTV1 70.2 66.5 64.0 65.5 ± 0.9 89.4 91.7 ± 2.3
PTV2 59.4 70.1 58.4 63.7 ± 1.3 98.3 99.2 ± 0.2
PTV3 50.4 59.5 49.6 54.5 ± 1.2 88.9 93.8 ± 0.9
Total 78.1 85.3 ± 2.7
IMRT2 PTV1 70.2 73.2 74.0 73.6 ± 1.4 99.0 98.6 ± 0.6
PTV2 59.4 72.0 60.0 64.6 ± 1.3 98.8 99.4 ± 0.2
PTV3 50.4 59.5 49.6 51.7 ± 0.7 88.9 91.2 ± 0.9
Total 87.0 89.4 ± 1.6
D is the prescribed dose by the radiation oncologist;
BED is the biological effective dose corresponding to the prescribed dose D;
D2Gy is the prescribed dose converted into a fractionation of 2 Gy;
D2Gy is the mean dose planned in each region of interest for a fractionation of 2 Gy averaged for all patients;
SD is the standard deviation for all patients;
PB is the expected tumour control probability for the prescribed dose D;
PB is the estimated average probability of tumour control for the planned dose distribution.
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Page 7 of 13radiation therapy technique all advantages, both in
terms of patient cure and toxicity, should be explored.
The dose escalation prescribed with IFP significantly
increased the probability of tumour control for all
patients compared to CONVT at the same time that a
large reduction in the probability of severe injuries was
also obtained (Figure 2). The estimated injury in the
parotids was reduced more than 20% while keeping the
maximum dose in the spinal cord below the tolerance
level of 45 Gy. However, the average probability of com-
plications in the oral cavity and in the mandible
increased since a larger dose was now deposited in these
structures (Figure 3).
Spinal cord, parotids, oral cavity and mandible are
some of the most important organs at risk in radiation
therapy of patients with head and neck tumours. Other
CONTRL. PAROTID IPS. PAROTID P/% or D/Gy
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Figure 3 Probability of response and dosimetric data for several organs at risk. Average values of the probability of complications in each
organ at risk, PI, the mean dose, Dmean and the maximum significant dose, Dmax. The error bars indicate the standard deviation of all planned
cases. The colour bars show the biologically converted dose to a fractionation schedule of 2 Gy per fraction. The grey bars show nominal or
physical dose values obtained with the prescribed fractionation. The larynx was not used during treatment planning in the past and therefore it
was not included in treatment planning optimization. However with the prescribed dose escalation and to maximize normal tissue sparing all
organs located close to the PTV should be delineated and considered during optimization.
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Page 8 of 13normal tissue structures located close to the PTV, e.g.
the larynx, oesophagus, brain, etc; are not generally con-
sidered during plan optimization. Conventional radiation
doses do not generally cause major damage in these
structures and therefore traditionally these were not
delineated. Although the prescribed dose escalation
resulted in a negligible probability of injury in these
organs, an increase in the mean and maximum dose was
obtained (Figure 3). Irradiation with new treatment con-
figurations added to a dose escalation may result in an
increase in the incidence of complications or even unex-
pected side-effects [37,38]. Thus most normal tissue
structures located in the vicinity of the PTV are now
routinely outlined and used for plan optimization.
With inverse IMRT additional therapeutic advantages
both in terms of tumour control but mostly in reducing
patient complications were obtained (Figure 2). An
increase in the probability of tumour control of almost
6% and 10% for IMRT1 and IMRT2, respectively, was
thus obtained compared to IFP (Figure 2). For IMRT1
this was mainly due to the better target volume coverage
since about the same mean biological dose was delivered
as for IFP. For IMRT2 the improvement in tumour con-
trol probability resulted also from the biological dose
escalation obtained by the shorter fractionation scheme
used (Figure 4).
The comparison between IFP and IMRT1 aimed at
quantifying the potential benefits of IMRT for the same
fractionation schedule. Thus the complete treatment
was composed by the delivery of three sequential plans
(Table 1). To accomplish international guidelines on
dose homogeneity in each plan, this resulted in signifi-
cant overdosages in the PTV2 and PTV3 in the final
dose matrix obtained by the plan addition of the multi-
ple plans (Table 3). This effect may be minimized when
the second or third treatment phase are optimized
based on the pre-planned dose distribution. However
this frequently resulted in dose inhomogeneities in the
following treatment phases with hot and cold spots in
the primary tumour with unpredictable outcomes.
Simultaneous integrated boost techniques, like IMRT2,
are thus advantageous since it is possible to tailor the
final dose distribution to the prescription of each target
volume. Overdosages, common in treatments with mul-
tiple phases, are thus more easily avoided (Figure 4)
reducing also the dose in the normal tissues (Figure 3).
Except for the normal tissues inside the PTVs, all
organs at risk benefited from inverse optimization treat-
ment techniques. The parotids and the oral cavity were
the structures that most gained with inverse IMRT. The
probability of mucositis was reduced to values below 5%,
significantly smaller than with IFP (p < 0.05) (Figure 3).
The calculated probability of severe xerostomia due to
the damage caused to the ipsilateral parotid was now
below 20% for a mean biological dose of 33 Gy and
below 10% due to the injury caused to the contralateral
parotid for a mean dose of 30 Gy. Based on the conclu-
sions of Eisbruch et al [25], a tolerance mean dose of 26
Gy is generally used. The optimization strategy in this
study was to spare the parotids as much as possible with-
out compromising target coverage. Still, on average this
dose level was not reached. Only in 43% of the studied
cases the parotids were irradiated with mean doses smal-
ler than 26 Gy (Figure 5). However, a strict comparison
with this tolerance dose cannot be made since differences
in structure delineation of the parotids and planning tar-
get volumes will certainly influence this value.
Different fractionation schemes were clinically imple-
mented intending to increase the therapeutic window
for head and neck tumours with fast proliferating cells
[21,28,29]. With IMRT2, for the same prescription dose,
a reduction in overall treatment time was obtained
through an increase in fraction size. The combination of
these factors may be beneficial for tumour cure but
0
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Figure 4 Probability of tumour control and dosimetric data for
the target volumes. Average values of the probability of tumour
control in each target volume, PB, the minimum significant dose,
Dmin, the mean dose, Dmean, the maximum significant dose, Dmax,
and the dose distribution standard deviation, SD. For illustration
purposes this standard deviation was multiplied by 10. The error
bars refer to the standard deviation of all planned cases. The colour
bars indicate the dose values converted to a fractionation scheme
of 2 Gy per fraction. The grey bars show the physical dose for the
prescribed fractionation. The difference between the physical dose
and converted dose to 2 Gy is more evident in the PTV1 due to
repopulation effects.
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Page 9 of 13should be carefully considered since fraction size is a
predictive factor for late patient morbidity [27]. How-
ever, for typical IMRT dose distributions with high con-
formity and steep dose gradients the dose per fraction
in the organs at risk located outside the target volume
may not necessarily be increased compared to conven-
tional techniques. IMRT2 was tested because minimiz-
ing the number of treatment phases brings practical,
dosimetric and radiobiological advantages. Overall treat-
ment time was reduced from 52 days with the three
phase treatment to 45 days with this two phase format.
The rational for the selected scheme was to maintain as
much as possible the conventional fractionation without
increasing the dose per fraction above 2.2 Gy or redu-
cing it to values below 1.8 Gy. Patients irradiated with
simultaneous integrated boost techniques with doses per
f r a c t i o nl a r g e rt h a n2 . 2G yh a v es h o w nu n f a v o u r a b l e
a c u t et o x i c i t y[ 1 6 , 1 8 ] .A tt he same time treatment out-
c o m ef o rd o s e sp e rf r a c t i o ns m a l l e rt h a n1 . 8G yi s
unpredictable since conventional knowledge on tumour
control is mostly based on fractions of around 2 Gy.
With the fractionation used with IMRT2 a biological
dose escalation in the PTV1, of about 10 Gy, was made
(Figure 4, Table 3). An increase in the average probabil-
ity of primary tumour control of more than 11% rela-
tively to IFP and 7% relatively to IMRT1 was thus
o b t a i n e d( p<0 . 0 5 ) .T h en e wp r o p o s e df r a c t i o n a t i o n
with IMRT2 may be beneficial in terms of tumour cure,
but it increased the dose per fraction in the PTV2 to
2.12 Gy relatively to the conventional fractionation of
1.8 Gy. Although nominal doses delivered in the organs
at risk with IMRT2 are about the same as for IMRT1,
the probability of late severe complications in the nor-
mal tissues adjacent to the PTV2, or even inside, was
slightly increased compared to IMRT1 (Figure 3). As a
result the average probability of total injury with IMRT2
was in average almost 5% higher than with IMRT1.
However this difference was not statistically significant.
Still, despite the therapeutic gain obtained in terms of
tumour control with IMRT2 (p < 0.05), the estimated
treatment outcome was about the same as with IMRT1
(Figure 2).
A progressive clinical implementation of a radiobiolo-
gical plan evaluation is recommended not only to com-
plement the conventional dosimetric analysis but also to
assess the accuracy of available dose-response data. The
large D50 value derived by Ågren et al [32] for the paro-
tids using Emami et al [39] empirical estimates, recently
validated by Deasy et al [40], was selected for this study
since it models better the incidence of late severe xeros-
tomia [4,5]. To quantify treatment outcome using the
concept of the probability of uncomplicated tumour
control only late severe complications, with an impor-
tance factor equal to tumour control and therefore with
a significant impact on quality of live, should be consid-
ered. The merit of the values estimated for treatment
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Figure 5 Mean dose and probability of complications for the parotids. Mean dose, Dmean (above) and probability of complications, PI
(below) in the ipsilateral and contralateral parotid for each of the seven studied cases. Horizontal colour lines show average values for all
patients. The dashed lines in the upper plots indicate the dose objective of 26 Gy generally used as the tolerance dose level in the parotids [25].
Dose values refer to biologically corrected dose to a fractionation of 2 Gy per fraction. Nasop. stands for nasopharynx, Orop. for oropharynx,
Hipop. for hipopharynx and Tong. for base of the tongue.
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Page 10 of 13outcome is entirely dependent on the quality of the
radiobiological models and respective dose response
parameters. Most historically empirically derived para-
meters are associated to well known uncertainties.
Therefore the estimated response values presented in
this study should be mostly regarded in relative terms.
Model validation, derivation of more accurate dose
response parameters and development of predictive
assays to determine individual patient radiosensitivity
are greatly needed. These are fundamental tools that
will allow a reliable estimation of the probability of indi-
vidual patient response that could then be used with
confidence in the clinical practice.
The clinical implementation of IMRT is very demand-
ing for a radiation therapy department but most of the
workload falls into the physicist and the radiation onco-
logist. Accurate structure delineation is now a funda-
mental step requiring multi-modality imaging and still,
it is one of the weakest links of the radiation therapy
chain [41]. A planning and quality control protocol
needs to be implemented and an accurate delivery can
only be guaranteed by the verification of the perfor-
mance of all the equipment involved in the treatment.
Thus, the complexity of the overall process recommends
for a slow and progressive learning curve. The introduc-
tion in our clinical practice of IFP prior to IMRT has
considerably helped in preparing the team for the more
demanding tasks. IFP is much more elaborate and com-
plex to plan than techniques based on simple parallel
opposed beam configurations taking six to eight hours
of planning time. Patient specific verifications consist
mostly of an independent monitor units calculation.
Therefore the clinical implementation of this technique
was straightforward. In contrast the implementation of
IMRT required a new planning optimization methodol-
ogy and the development and implementation of
patient-specific verification tools that are still being
improved. With IMRT the workload of each plan, both
in planning and quality assurance, has increased by
more than three times presently limiting the delivery of
IMRT to all patients. Furthermore, not all patients can
undergo the longer IMRT treatment times extended by
the 3 D patient verification setup and irradiation time.
For such patients IFP can perform better than old tech-
niques based on simpler parallel opposed uniform beam
configurations. Otherwise inversely optimized IMRT due
to its significant therapeutic benefits should be selected
over directly optimized treatment technique.
Conclusions
Inverse IMRT improved treatment outcome by 56% rela-
tively to CONVT due to a significant improvement in the
probability of tumour control and complications. The
shorter overall treatment time and the larger dose per
fraction obtained with IMRT2 resulted in a biological dose
escalation in the primary tumour of about 10 Gy and an
increase in the probability of tumour control of more than
10% compared to the conventional fractionation of 1.8 Gy
used with IFP. The probability of complications in the par-
otids was reduced by 40% compared to CONVT and the
probability of injury in the oral cavity was reduced by 10%
compared to IFP. The small differences in the probability
of complications obtained between the two IMRT techni-
ques studied do not justify the extra workload required to
implement a three phase treatment.
With IFP treatment outcome was 37% less than with
IMRT but 19% higher than with CONVT. Thus during
this transition period IFP has shown to be an efficient
option until high resolution IMRT cannot be delivered
to all patients with head and neck tumours
The implementation of forward and inverse IMRT
techniques may significantlyi n c r e a s et h ep r o b a b i l i t yo f
tumour control and reduce the probability of complica-
tions. The increase in the probability of tumour control
may translate into a longer life expectancy giving time to
unobserved side effects to emerge. The dose escalation
prescribed has also increased the dose in organs generally
not at risk that should be included in the optimization of
the plan on a routine basis. This study was mostly based
on a radiobiological evaluation of the benefits of different
radiation therapy techniques since the impact of the frac-
tionation schedule on treatment outcome can be
assessed. In addition, a physical evaluation of the plans
was also made. However, neither of these evaluation
methods replaces the invaluable use of a proper follow-
up to assess the real outcome of the patients.
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